NO20054049L - Fremgangsmate for diagnose og behandling. - Google Patents
Fremgangsmate for diagnose og behandling.Info
- Publication number
- NO20054049L NO20054049L NO20054049A NO20054049A NO20054049L NO 20054049 L NO20054049 L NO 20054049L NO 20054049 A NO20054049 A NO 20054049A NO 20054049 A NO20054049 A NO 20054049A NO 20054049 L NO20054049 L NO 20054049L
- Authority
- NO
- Norway
- Prior art keywords
- subject
- detecting
- cell
- aberrant
- molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003900777A AU2003900777A0 (en) | 2003-02-21 | 2003-02-21 | A method of diagnosis and treatment |
AU2003901126A AU2003901126A0 (en) | 2003-03-06 | 2003-03-06 | A method of diagnosis and treatment - ii |
PCT/AU2004/000223 WO2004073739A1 (fr) | 2003-02-21 | 2004-02-23 | Procede de diagnostic et de traitement |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054049D0 NO20054049D0 (no) | 2005-08-31 |
NO20054049L true NO20054049L (no) | 2005-11-11 |
Family
ID=32909159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054049A NO20054049L (no) | 2003-02-21 | 2005-08-31 | Fremgangsmate for diagnose og behandling. |
Country Status (8)
Country | Link |
---|---|
US (2) | US9063155B2 (fr) |
EP (1) | EP1599226B1 (fr) |
JP (3) | JP5339676B2 (fr) |
KR (1) | KR20050114217A (fr) |
CN (1) | CN103293316B (fr) |
CA (1) | CA2516335A1 (fr) |
NO (1) | NO20054049L (fr) |
WO (1) | WO2004073739A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4628674B2 (ja) | 2001-09-12 | 2011-02-09 | ザ ウォルター アンド エリザ ホール インスティテュートオブ メディカル リサーチ | 診断および治療の方法ならびにそのために有用な作用物質 |
KR101314461B1 (ko) * | 2004-05-12 | 2013-10-07 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 감염 치료를 위한 겔솔린의 용도 |
GB0425324D0 (en) * | 2004-11-17 | 2004-12-22 | Univ Edinburgh | Assay method |
WO2006102716A1 (fr) * | 2005-04-01 | 2006-10-05 | Medvet Science Pty. Ltd. | Procede pour le diagnostic et le traitement et agents utiles pour celui-ci |
WO2007097377A1 (fr) | 2006-02-24 | 2007-08-30 | The Furukawa Electric Co., Ltd. | Systeme de quantification de biomolecules par cytometrie de flux, procede de quantification, systeme de detection et d'echantillonnage de cellules, procede de detection et d'echantillonnage, particule de silice fluorescente a utiliser dans ces systemes et kit comprenant de multiples particules de silice combinees ensemble |
PT3279663T (pt) | 2006-03-15 | 2021-09-24 | Brigham & Womens Hospital Inc | Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias |
EP2082235B1 (fr) * | 2006-10-11 | 2018-10-03 | Medvet Science Pty. Ltd. | Procede de diagnostic et agents convenant a cet effet |
CA2666184A1 (fr) * | 2006-10-11 | 2008-04-17 | Medvet Science Pty. Ltd. | Utilisation d'un agent endommageant l'adn et d'un ligand pour le traitement de cancer |
KR101049583B1 (ko) * | 2009-06-30 | 2011-07-14 | 한국과학기술연구원 | 3-인돌아세토니트릴을 유효성분으로 함유하는 유두갑상선암 진단용 마커 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5518881A (en) * | 1993-11-02 | 1996-05-21 | Flinders Medical Centre | Transfected cell lines expressing autoantigens and their use in immunoassays for the detection of autoimmune disease |
EP1071327A4 (fr) * | 1998-04-22 | 2004-09-29 | Merck & Co Inc | Fragments auto-antigenes, methodes et dosages |
CA2389364A1 (fr) * | 1999-11-01 | 2001-05-10 | Universiteit Van Amsterdam | Technique de detection de carcinomes chez un mammifere |
IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
EP1516186B1 (fr) | 2002-06-26 | 2010-02-17 | University Of Louisville Research Foundation, Inc. | Procede de detection de l'apoptose |
-
2004
- 2004-02-23 EP EP04713491A patent/EP1599226B1/fr not_active Expired - Lifetime
- 2004-02-23 KR KR1020057015494A patent/KR20050114217A/ko not_active Application Discontinuation
- 2004-02-23 US US10/546,552 patent/US9063155B2/en active Active
- 2004-02-23 WO PCT/AU2004/000223 patent/WO2004073739A1/fr active Application Filing
- 2004-02-23 JP JP2006501372A patent/JP5339676B2/ja not_active Expired - Lifetime
- 2004-02-23 CN CN201310103253.7A patent/CN103293316B/zh not_active Expired - Lifetime
- 2004-02-23 CA CA002516335A patent/CA2516335A1/fr not_active Abandoned
-
2005
- 2005-08-31 NO NO20054049A patent/NO20054049L/no not_active Application Discontinuation
-
2013
- 2013-04-19 JP JP2013088647A patent/JP5847755B2/ja not_active Expired - Lifetime
-
2015
- 2015-05-06 US US14/705,638 patent/US20150377890A1/en not_active Abandoned
- 2015-06-10 JP JP2015117156A patent/JP2015172601A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1599226A1 (fr) | 2005-11-30 |
JP5847755B2 (ja) | 2016-01-27 |
US9063155B2 (en) | 2015-06-23 |
US20070042432A1 (en) | 2007-02-22 |
US20150377890A1 (en) | 2015-12-31 |
EP1599226B1 (fr) | 2012-09-19 |
JP2013178261A (ja) | 2013-09-09 |
CN103293316A (zh) | 2013-09-11 |
JP2015172601A (ja) | 2015-10-01 |
JP2006518453A (ja) | 2006-08-10 |
CN103293316B (zh) | 2016-09-28 |
JP5339676B2 (ja) | 2013-11-13 |
NO20054049D0 (no) | 2005-08-31 |
CA2516335A1 (fr) | 2004-09-02 |
EP1599226A4 (fr) | 2007-11-21 |
KR20050114217A (ko) | 2005-12-05 |
WO2004073739A1 (fr) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054049L (no) | Fremgangsmate for diagnose og behandling. | |
RU2010135526A (ru) | Новый способ количественного определения и охарактеризования микровезикул в жидкостях организма человека | |
Kallwitz | Sarcopenia and liver transplant: The relevance of too little muscle mass | |
Zhu et al. | Postmortem cardiac troponin T levels in the blood and pericardial fluid. Part 1. Analysis with special regard to traumatic causes of death | |
Sekijima et al. | High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly | |
Holmvang et al. | Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (a thrombin inhibition in myocardial ischemia [TRIM] substudy) | |
Banasik et al. | Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss | |
ES2534432T3 (es) | Biomarcadores de riñón sano | |
JP2011510309A5 (fr) | ||
Lee et al. | The geo-epidemiology of temporal (giant cell) arteritis | |
NO20075104L (no) | Fremgangsmate for diagnostikk og behandling og midler nyttige for dette | |
Titan et al. | Metabolites related to eGFR: Evaluation of candidate molecules for GFR estimation using untargeted metabolomics | |
WO2015060317A1 (fr) | Procédé de dépistage de maladie neurodégénérative | |
Lauridsen et al. | Effects of common chronic medical conditions on psychometric tests used to diagnose minimal hepatic encephalopathy | |
BRPI0512948A (pt) | biomarcadores de mal de alzheimer | |
EP3943948A1 (fr) | Procédé d'aide à l'évaluation de l'état des reins, système d'évaluation de l'état des reins et programme d'évaluation de l'état des reins | |
Kirkpantur et al. | Utility of the Doppler ultrasound parameter, resistive index, in renal transplant histopathology | |
EP2541253B1 (fr) | Méthode d'essai pour une lésion rénale aiguë | |
Harmacek et al. | Molecular diagnosis of antibody-mediated rejection: Evaluating biopsy-based transcript diagnostics in the presence of donor-specific antibodies but without microvascular inflammation, a single-center descriptive analysis | |
Spasovski et al. | Urinary proteomics in kidney transplantation | |
Krishnan et al. | 221: exhaled breath condensate pepsin: A new noninvasive marker of GERD after lung transplantation | |
CN113631923A (zh) | 辅助肾病况的评价的方法、肾病况的评价系统及肾病况的评价程序 | |
RU2007141205A (ru) | Композиция, набор и способ мечения клеток | |
RU2810455C1 (ru) | Способ ранней диагностики тубулярной дисфункции почек у лиц с сахарным диабетом 2 типа и гиперхолестеринемией | |
US20200064344A1 (en) | Use of serum 2-cysteine peroxiredoxins (2-cys-prdx) as biomarkers of chronic kidney diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |